BLU-451 (EGFR exon 20 insertion inhibitor) ✔️

Blueprint Medicines

Confirmed correct on June 15, 2024 on PubChem.

BLU-451 (formerly LNG-451) is an oral, CNS-penetrant EGFR inhibitor specific for exon 20 insertions. It is being developed by Blueprint Medicines (BPMC 0.00%↑) and is currently in ph1/2 for the treatment of advanced cancers with this mutation (NCT05241873).